#South Korea #Munich #Seegene #STAgora #PCR Workflow

Seegene Showcases STAgora™ at ESCMID Global 2026

Seegene Inc., a leader in molecular diagnostics, recently made headlines at ESCMID Global 2026 in Munich by unveiling its revolutionary platform STAgora™. This advanced data analytics tool is designed to integrate real-time insights into existing automated PCR workflows, thereby transforming how health professionals engage with diagnostic data.

The event, held from April 17 to 21, 2026, attracted attention from a diverse array of medical practitioners, including laboratory specialists, researchers, and industry stakeholders who explored Seegene's innovative offerings. Visitors to Seegene’s booth were treated to immersive experiences, particularly through the “STAgora™ Experience Zone,” which featured interactive demonstrations and simulations displaying the potential of the STAgora™ platform and its integration with the CURECA™ automated PCR workflow.

Setting a New Standard in Diagnostic Testing

One of the focal points during the conference was Seegene’s presentation of its key message, "From Numbers to Insights." The aim was to demonstrate how automated testing infrastructure and real-time data analytics capabilities can work in synergy to deliver meaningful interpretations of emerging health trends.

According to Young Seag Baeg, the new head of new business development at Seegene, STAgora™ is strategically developed to gather and process real-time PCR testing data from across the globe. This functionality is geared towards providing clearer insights into infectious disease trends based on aggregated statistical data, thereby enhancing the understanding of public health dynamics.

“STAgora™ allows users to visualize infection trends and investigate results comparatively,” Young Seag Baeg stated. The tech empowers healthcare professionals with the capability to analyze aggregated testing outcomes alongside regional epidemiological data, a feature that garnered significant interest among conference attendees.

CURECA™: Streamlining Diagnostic Efforts

In addition to STAgora™, Seegene showcased a demonstration version of CURECA™, an automated workflow system that comprises various stages including pre-treatment, nucleic acid extraction, amplification, and result processing. This modular system sparked thorough discussions among participants, particularly regarding its practical implementation in routine laboratory environments.

A clinician from a German university hospital noted that STAgora™ offers an intuitive interface for exploring and visualizing aggregated test data trends. The ability to access real-time insights on regional infection rates and aggregated testing outcomes proved to be particularly intriguing, as it allows for proactive health decision-making.

Daniel Shin, Executive Vice President and Head of Sales and Marketing at Seegene, remarked on the strong interest in STAgora™ throughout the event. He emphasized that the company aims to broaden pilot programs and collaborative evaluations with healthcare institutions and laboratories, facilitating further exploration and potential future adoption of the platform.

Expanding Collaborative Efforts for Impact

During the conference, dialogues unfolded between Seegene and leading global partners regarding the adoption and validation of STAgora™ and CURECA™. Additionally, dedicated sessions were organized for healthcare and laboratory professionals, especially across Europe, to highlight use cases and possible applications of the emerging technologies.

Seegene revealed plans to strengthen collaborations with clinical, academic, and research partners to enhance implementation and validation strategies for STAgora™. The ultimate goal is to fast-track real-world adoption of this revolutionary technology within international healthcare settings.

About Seegene

Seegene is an international molecular diagnostics company boasting over 25 years of expertise in developing and manufacturing syndromic real-time PCR technology. Widely recognized for its multiplex PCR technology, Seegene has successfully provided over 340 million COVID-19 tests to over 100 countries, demonstrating its capabilities amid global health challenges. With a vision to create an integrated diagnostic ecosystem, the company continues to innovate through advanced technologies like STAgora™ and CURECA™, aiming to broaden access to molecular diagnostic technologies and enhance global preparedness against infectious diseases.

For further information about Seegene and its products, visit Seegene’s website.